Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Polis

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
HIV Clinical Trials|August 9, 2013
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infectionK J Cortez, M A Proschan, L Barrett, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1995
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruriaM A Polis, K M Spooner, B F Baird, et al.
AIDS (London, England)|September 14, 2000
Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppressionJ M Orenstein, N Bhat, C Yoder, et al.
Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.
The New England Journal of Medicine|October 31, 1996
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virusJ A Kovacs, S Vogel, J M Albert, et al.
The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
The Journal of Infectious Diseases|March 18, 2006
Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected personsR A Lempicki, M A Polis, J Yang, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
American Journal of Ophthalmology|March 24, 1999
Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panelD F Martin, J P Dunn, J L Davis, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
HIV Clinical Trials|August 9, 2013
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infectionK J Cortez, M A Proschan, L Barrett, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1995
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruriaM A Polis, K M Spooner, B F Baird, et al.
AIDS (London, England)|September 14, 2000
Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppressionJ M Orenstein, N Bhat, C Yoder, et al.
Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.
The New England Journal of Medicine|October 31, 1996
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virusJ A Kovacs, S Vogel, J M Albert, et al.
The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.
Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.
The Journal of Infectious Diseases|March 18, 2006
Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected personsR A Lempicki, M A Polis, J Yang, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
American Journal of Ophthalmology|March 24, 1999
Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panelD F Martin, J P Dunn, J L Davis, et al.
Pageof 8